Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Level V
Where this comes from
- Record sourced from PubMed, PMID 27797957.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
Medical subject headings
- Breast Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases
- Prostatic Neoplasms